BioCentury
ARTICLE | Clinical News

Edurant rilpivirine: Phase IIb data

November 9, 2015 8:00 AM UTC

The 96-week, open-label, international Phase IIb LATTE 2 trial in 286 evaluable patients with HIV-1 infection showed that a long-acting intramuscular regimen of cabotegravir plus rilpivirine given every 4 or 8 weeks as suppressive maintenance therapy each met the primary endpoint of maintaining the proportion of patients with plasma HIV-1 RNA levels of <50 copies/mL at week 32 vs. patients who continued to received once-daily oral cabotegravir plus abacavir/lamivudine (94% and 95%, respectively, vs. 91%). The trial enrolled patients who were naive to antiretroviral therapy (ART) and who achieved viral suppression on oral therapy with once-daily cabotegravir plus abacavir/lamivudine. The most common adverse event reported was injection-site pain. There were 1 case of protocol-defined virologic failure in the 8-week cabotegravir plus rilpivirine arm and 1 case in the cabotegravir plus abacavir/lamivudine arm. Neither patient had evidence of resistance at failure. ...